Dermira to Present Data from DRM01 and DRM04 Clinical Programs at Fall Clinical Dermatology Conference
13 oct. 2016 07h30 HE
|
Dermira, Inc.
MENLO PARK, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
03 oct. 2016 02h00 HE
|
Dermira, Inc.
BRUSSELS, Belgium and MENLO PARK, Calif., Oct. 03, 2016 (GLOBE NEWSWIRE) -- UCB (Euronext:UCB) and Dermira, Inc. (NASDAQ:DERM) today announced topline results from CIMPASI-2, a Phase 3,...
Dermira Presents Data from DRM04 Phase 3 Clinical Program in Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
01 oct. 2016 03h05 HE
|
Dermira, Inc.
MENLO PARK, Calif., Oct. 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
28 sept. 2016 07h30 HE
|
Dermira, Inc.
MENLO PARK, Calif., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Licenses DRM04 to Maruho for Hyperhidrosis in Japan
20 sept. 2016 16h05 HE
|
Dermira, Inc.
Terms include $25 million upfront license payment to DermiraMaruho to fund all development and commercial costs for DRM04 in Japan MENLO PARK, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) --...
Dermira Acquires Option to License Exclusive Rights for up to Three Early-Stage Programs from Takeda
12 sept. 2016 07h30 HE
|
Dermira, Inc.
MENLO PARK, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Reports Second Quarter 2016 Financial Results and Provides Corporate Update
08 août 2016 16h12 HE
|
Dermira, Inc.
Reported Topline Results for Two Late-Stage Clinical ProgramsRaised Approximately $136 Million in Net Proceeds from Follow-on Public OfferingUpdates Guidance for Topline Phase 3 CIMZIA®...
Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
13 juin 2016 16h05 HE
|
Dermira, Inc.
MENLO PARK, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Prices $126 Million Public Offering of Common Stock
08 juin 2016 07h00 HE
|
Dermira, Inc.
MENLO PARK, Calif., June 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira to Present Preclinical Data from DRM01 Acne Program at the Society for Investigative Dermatology 75th Annual Meeting
11 mai 2016 16h05 HE
|
Dermira, Inc.
MENLO PARK, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...